US regulator asks for more info on Pfizer/Allergan merger

The US competition authority has asked for further information from Pfizer and Allergan on their proposed $160 billion merger, which will create the world’s largest pharma company.

In a joint statement the companies said this “second request” from the Federal Trade Commission was anticipated as part of the regulatory process under US takeover laws.

The companies said they continue to expect the transaction to complete in the second half of 2016.

Completion of the deal depends on clearance of US regulations and regulatory approvals in other jurisdictions including the EU, approval from both sets of shareholders, and the completion of Allergan’s sale of its generics business to Teva.

Related stories:

Pfizer re-files Xeljanz in Europe for rheumatoid arthritis

Allergan deal will go ahead, says Pfizer chief

Don't miss your daily pharmaphorum news.
SUBSCRIBE free here.